Quarterly report pursuant to Section 13 or 15(d)

PROPERTY AND EQUIPMENT, NET

v3.23.3
PROPERTY AND EQUIPMENT, NET
9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT, NET

NOTE 4 – PROPERTY AND EQUIPMENT, NET

 

Property and equipment, net consisted of the following (in thousands):

 

    September 30,
2023
    December 31,
2022
 
    (in thousands)  
Property and equipment, net:                
Land   $ 8,011     $ 8,011  
Land improvements                      326                        79  
Buildings               65,825                 65,644  
Office furniture and equipment     2,355       1,893  
Laboratory equipment     21,506       18,440  
Leasehold improvements       34       34  
Construction in progress     1,204       1,366  
      99,261       95,467  
Less: Accumulated depreciation and amortization     (4,395 )     (1,653 )
    $ 94,866     $ 93,814  

 

On October 1, 2021, the Company completed the acquisition of its approximately 45,000 square foot research and development facility in Frederick, Maryland totaling $17.5 million, to process development activities. Of the total purchase price, $2.1 million was allocated to the value of land acquired, and $13.9 million was allocated to buildings, and approximately $1.5 million was allocated to office furniture and equipment and laboratory equipment. During 2022, the assets became ready for the intended use and were placed in service.

 

On September 28, 2020, the Company completed the purchase of its approximately 45,000 square foot facility in Dartmouth, Massachusetts for $4.0 million, to house its new Advanced Development Center for the development and manufacturing of vaccines. Of the total purchase price, $1.2 million was allocated to the value of land acquired, and $2.8 million was allocated to buildings. Additionally, the Company incurred approximately $38.8 million of costs during the year ended December 31, 2022, bringing total costs incurred-to-date to $61.6 million, of which the majority related to the build-out of the facility. During 2022, the assets became ready for the intended use and were placed in service.

 

On December 23, 2020, the Company completed the purchase of its approximately 44-acre site in Hamilton, Montana for $4.5 million, for the construction of a vaccine development and commercial scale manufacturing facility. As of September 30, 2023, the asset was not ready for its intended use.

 

During the quarter ended September 30, 2023, property and equipment with a net book value of approximately $0.8 million were sold for net proceeds of approximately $1.0 million.